article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. With 27.5%

article thumbnail

Compliance to convenience: understanding the latest innovations in capsule formulation

Pharmaceutical Technology

When it comes to pharmaceutical, nutritional or cosmeceutical dosing, some of the most crucial parameters are safety, product effectiveness and patient adherence. Softgels have now achieved strong recognition in the prescription, consumer health and supplements markets. billion by 2028, at a CAGR of 12.6%.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

Under the pathway, manufacturers can use safety and efficacy data from existing products in their applications for their own products. This product would be a more potent prescription version than the OTCs, Casberg notes. This pathway is being used to produce more naloxone products, which reverse opioid overdoses.

article thumbnail

The U.S. health insurance market is undergoing a post-pandemic sea change

Clarivate

Many insurers use similar networks for Medicaid and exchange plans, so shifting to an exchange plan is less likely to cause a lapse in coverage or abandonment of prescription drugs or maintenance medications that control chronic conditions.